Information about Mistletoe: Harvesting and cultivation, sexes, reproduction and germination.

A major 30-year-long study with more than 35,000 participants reports that extract of mistletoe (Iscador®) greatly improves survival rate for a wide variety of cancers, including breast cancer. Study participants who augmented conventional therapy with mistletoe extract survived 40% longer compared with those who didn’t use the plant therapy.

After administering standardized mistletoe extract, Iscador®, the investigations showed a temporarily improved function of the microcirculation and an increased adhesion and transmigration of white blood cells in the target tissue areas. (article in 3 parts)

After administering standardized mistletoe extract, Iscador®, the investigations showed a temporarily improved function of the microcirculation and an increased adhesion and transmigration of white blood cells in the target tissue areas. (article in 3 parts)

After administering standardized mistletoe extract, Iscador®, the investigations showed a temporarily improved function of the microcirculation and an increased adhesion and transmigration of white blood cells in the target tissue areas. (article in 3 parts)

The results show no evidence of stimulation of tumor growth by any of the three Iscador® preparations, comprising central nervous system, gastric, non-small cell lung, mammary, prostate, renal and uterine cancer cell lines, as well as cell lines from hematological malignancies and melanomas.

Multicenter Cohort Study. Adjuvant treatment with mistletoe extract can increase the tolerability of conventional cancer treatment, improve patient quality of life, and lengthen tumor free survival, Dr. Paul R. Bock reported.

The results of the present study confirmed the safety of the complementary therapy for patients with primary, non-metastatic mammary carcinoma with Iscador® and showed considerably fewer ADRs attributed to concurrent conventional therapy, as well as reduced disease and treatment-associated symptoms, and suggested a prolonged overall survival in the Iscador® group as compared with controls.

Iscador may have potential as a non toxic therapy for chronic hepatitis C treatment.

An important aspect of the current work and research conducted by the Department of Clinical research at Herdecke Hospital in Germany is the development and application of methods to explore the rhythms/oscillations of heartbeat and respiration of the human organism. This link leads to a list of additional studies on this theme. Go to 'Publications' on the webpage of the Herdecke Hospital.